Skip to content

Study · Not a test of the peptide alone · 2022

3 results

Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trial.

Franek E, Gerstein HC, Riddle MC, Nicolay C, Hickey A, Botros FT, Loo LS

Diabetes, obesity & metabolism30 May 2022Cited by 6 (Europe PMC)

PMID35546279 (opens in a new tab)PMCIDPMC9543284 (opens in a new tab)DOI10.1111/dom.14760 (opens in a new tab)PepBankPUB-35546279
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

  1. 01HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In REWIND participants, dulaglutide's BMI reduction did not differ by baseline HbA1c subgroup.

    In plain wordsDulaglutide's effect on BMI did not differ between baseline blood sugar subgroups.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeBMI reduction interaction
    Study

    n = 9,876

    Comparator
    Treatment effects across baseline HbA1c subgroups
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    There was no evidence of a differential dulaglutide treatment effect on body mass index (BMI) reduction, cardiovascular or safety outcomes of interest between the baseline HbA1c subgroups.
    2 context sentences
    Summary · context
    To assess cardiovascular, glycaemic, weight and safety outcomes of long-term treatment with dulaglutide 1.5 mg compared with placebo in patients with a baseline HbA1c of less than 7% versus 7% or higher.
    Summary · context
    Intention-to-treat analyses were performed on REWIND participants with a baseline HbA1c measurement, using Cox proportional hazards regression and mixed model for repeated measures.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  2. 02HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In REWIND participants, cardiovascular treatment effects of dulaglutide did not differ by baseline HbA1c subgroup.

    In plain wordsDulaglutide's cardiovascular effects did not differ between baseline blood sugar subgroups.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeCardiovascular outcome interaction
    Study

    n = 9,876

    Comparator
    Treatment effects across baseline HbA1c subgroups
    Outcome group
    Cardiovascular events · Cardiovascular

    Source sentences

    Summary
    There was no evidence of a differential dulaglutide treatment effect on body mass index (BMI) reduction, cardiovascular or safety outcomes of interest between the baseline HbA1c subgroups.
    2 context sentences
    Summary · context
    To assess cardiovascular, glycaemic, weight and safety outcomes of long-term treatment with dulaglutide 1.5 mg compared with placebo in patients with a baseline HbA1c of less than 7% versus 7% or higher.
    Summary · context
    Intention-to-treat analyses were performed on REWIND participants with a baseline HbA1c measurement, using Cox proportional hazards regression and mixed model for repeated measures.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  3. 03HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In REWIND participants, dulaglutide reduced HbA1c more in the higher baseline HbA1c subgroup, with a significant treatment interaction.

    In plain wordsDulaglutide reduced blood sugar more in the subgroup with higher starting blood sugar.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c change interaction
    Study

    n = 9,876

    Comparator
    Treatment effects across baseline HbA1c subgroups
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Treatment-by-baseline HbA1c group interaction was significant for HbA1c change from baseline (P < .001), with a greater reduction in the subgroup with higher baseline HbA1c values.
    2 context sentences
    Summary · context
    To assess cardiovascular, glycaemic, weight and safety outcomes of long-term treatment with dulaglutide 1.5 mg compared with placebo in patients with a baseline HbA1c of less than 7% versus 7% or higher.
    Summary · context
    Intention-to-treat analyses were performed on REWIND participants with a baseline HbA1c measurement, using Cox proportional hazards regression and mixed model for repeated measures.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01394952

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Eli Lilly and Companyn = 9,90122 Jul 2011 to 21 Aug 2018

Cardiovascular Disease · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 8 Oct 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.